SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG):
2010 Fourth Quarter Financial Results Year-Over-Year (Unaudited)
* Non-GAAP Total Revenue Increased Approximately 38 Percent to Approximately $1.05 Billion; GAAP Total Revenue Approximately $1.06 Billion
* Global REVLIMID Net Product Sales Increased Approximately 42 Percent to Approximately $708 Million
* Global VIDAZA® Net Product Sales Increased Nearly 20 Percent to Approximately $140 Million
* Global THALOMID® Net Product Sales of Approximately $91 Million
* ABRAXANE® Net Product Sales of Approximately $71 Million (Since October 15, 2010 Closing of Abraxis BioScience Acquisition)
* Non-GAAP Diluted Earnings Per Share Increased Nearly 18 Percent to Approximately $0.73; GAAP Diluted Earnings Per Share Approximately $0.41 (Includes Impact of Acquisition of Abraxis BioScience)
